KALA BIO, Inc.
Arlington, Massachusetts, United States · Biotechnology, Health Care, Therapeutics
Kala Pharmaceuticals develops novel treatments for diseases that affect mucosal tissues.
Key facts
- Headquarters
- Arlington, Massachusetts, United States
- Employees
- 38
- Industries
- Biotechnology, Health Care, Therapeutics
- Status
- Public (KALA)
- Company page
Recent activity at KALA BIO, Inc.
- : KALA BIO
- : SEC 8-K (8.01):
- : SEC 8-K (8.01): The Company announced a Reverse Stock Split on November 12, 2026, via a press release. This strategic decision was made to adjust the company’s stock structure, which may enhance the stock’s marketability and attract more institutional investors. The announcement includes a Certificate of Amendment to the Restated Certificate of Incorporation, reflecting this change. The implications of the Reverse Stock Split could positively impact the share price and overall market perception of KALA BIO, Inc.
- : SEC 8-K (1.01):
- : SEC 8-K (8.01): On September 9, 2026, KALA BIO, Inc. announced that its Board of Directors has scheduled the next annual meeting of stockholders for November 3, 2026. This change in date surpasses the 30-day threshold from the previous year's annual meeting, thus necessitating a formal announcement and the setting of a new deadline for shareholder proposals in compliance with Rule 14a-8 under the Securities Exchange Act. The company will provide further details regarding the meeting's time, location, and agenda in its proxy statement, emphasizing their ongoing governance and communication with stakeholders.
- : SEC 8-K (3.01): On August 27, 2026, KALA BIO, Inc. received a Staff Determination Letter from Nasdaq regarding its non-compliance with the minimum bid price requirement, where the closing bid price of the Company's common stock has been below $1.00 per share for 30 consecutive business days. The event is significant as it places pressure on KALA BIO's continued listing on Nasdaq, requiring the company to address this issue or risk potential delisting. The notification cites the period of non-compliance specifically from July 16 to August 26, 2026, which serves as a crucial timeline for the company's corrective measures.
- : SEC 8-K (8.01): On July 22, 2026, KALA BIO, INC. filed a prospectus supplement pursuant to Rule 424(b) under the Securities Act of 1933 related to the offering of securities under its effective Registration Statement on Form S-3 (File No. 333-295667). This filing includes a legal opinion regarding the validity of the securities being offered, which is important for investors assessing the integrity of the investment opportunity. The legal opinion is attached as Exhibit 5.1, providing assurance on the legality of the offerings. The strategic implications of this prospectus supplement may enable the company to raise capital for future growth initiatives.
- : SEC 8-K (8.01): On May 7, 2026, KALA BIO, Inc. announced a Reverse Stock Split through a press release. This action involves adjusting the number of outstanding shares to increase the stock price and potentially improve its market perception. The press release serves to inform shareholders and the market about this strategic change in the company's capital structure. This kind of action typically aims to enhance shareholder value and may be part of a broader strategy to meet listing requirements or attract institutional investors.
- : SEC 8-K (1.01): On March 3, 2026, KALA BIO, Inc. entered into a Platform Development and Exclusive License Agreement with 2624465 Ontario Inc. (Younet AI), allowing KALA BIO a worldwide exclusive license to Younet's biomedical AI research platform known as the Researgency Platform. The agreement has an Initial Term of 12 months and can be renewed annually upon notice. The financial considerations include a total cash payment of up to $530,000 for the Initial Term, with $80,000 paid upfront and an additional $450,000 payable in monthly installments if continued development is elected. KALA BIO will also issue 5,000,000 shares of its common stock to Younet within 10 business days of the effective date, with similar terms for any renewal periods. An option for KALA BIO to acquire all equity interests of Younet is also included.
- : SEC 8-K (5.02):
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
KALA BIO, Inc. funding history
| Date | Round | Amount |
|---|---|---|
| Mar 2026 | Venture | $1.8M |
| Nov 2021 | Venture | $16.1M |
| Apr 2016 | Venture | $67.9M |
| Aug 2015 | Venture | $7.0M |
Leadership
- Mark Iwicki, Executive Officer, Director
- Andrew Koven, Director
- Gregory Perry, Director
- Gregory Grunberg, Director
- Robert Paull, Director
- Howard Rosen, Director
- C. Myers, Director
- Mark Blumenkranz, Director
- Chen Yu, Director
- Rajeev Shah, Director
- Greg Grunberg, Director
Verified email and direct lines for KALA BIO, Inc.’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
KALA BIO, Inc. files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Companies similar to KALA BIO, Inc.
- Candel Therapeutics · Biotechnology, Health Care, Therapeutics
- DiaMedica Therapeutics · Biotechnology, Health Care, Therapeutics
- GC Therapeutics · Biotechnology, Health Care, Therapeutics
- Epicrispr Biotechnologies · Biotechnology, Health Care, Therapeutics
- Korsana Biosciences · Biotechnology, Health Care, Therapeutics
About KALA BIO, Inc.: questions and answers
What does KALA BIO, Inc. do?
Kala Pharmaceuticals develops novel treatments for diseases that affect mucosal tissues.
Where is KALA BIO, Inc. headquartered?
KALA BIO, Inc. is headquartered in Arlington, Massachusetts, United States.
How many employees does KALA BIO, Inc. have?
KALA BIO, Inc. has about 38 employees.
Has KALA BIO, Inc. raised funding?
Yes. Fundz has recorded 4 funding events for KALA BIO, Inc.. The most recent, $1.8M, was in Mar 2026.
What is the latest news on KALA BIO, Inc.?
On Mar 3, 2026, KALA BIO
Is KALA BIO, Inc. a public company?
Yes. KALA BIO, Inc. is publicly traded under the ticker KALA.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy